Aura Biosciences (NASDAQ:AURA) Receives Buy Rating from HC Wainwright

Aura Biosciences (NASDAQ:AURA)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a report released on Thursday,Benzinga reports. They currently have a $22.00 price objective on the stock. HC Wainwright’s target price points to a potential upside of 112.97% from the company’s current price.

Other equities research analysts have also recently issued research reports about the company. Evercore ISI upgraded Aura Biosciences to a “strong-buy” rating in a report on Monday, September 16th. Lifesci Capital raised shares of Aura Biosciences to a “strong-buy” rating in a research note on Monday, September 9th. Cowen restated a “buy” rating on shares of Aura Biosciences in a report on Friday, October 18th. BTIG Research boosted their price objective on shares of Aura Biosciences from $21.00 to $24.00 and gave the company a “buy” rating in a research report on Friday, October 18th. Finally, JMP Securities raised their target price on shares of Aura Biosciences from $19.00 to $23.00 and gave the stock a “market outperform” rating in a research report on Friday, September 13th. Five research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $23.00.

Aura Biosciences Stock Performance

Shares of NASDAQ AURA opened at $10.33 on Thursday. Aura Biosciences has a one year low of $6.63 and a one year high of $12.38. The firm has a market capitalization of $512.47 million, a P/E ratio of -5.97 and a beta of 0.33. The company’s fifty day moving average is $9.75 and its two-hundred day moving average is $8.50.

Aura Biosciences (NASDAQ:AURA) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.42) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $0.02. On average, sell-side analysts forecast that Aura Biosciences will post -1.7 earnings per share for the current fiscal year.

Insider Activity at Aura Biosciences

In other news, CTO Mark Plavsic sold 7,383 shares of the firm’s stock in a transaction dated Wednesday, October 16th. The stock was sold at an average price of $9.85, for a total value of $72,722.55. Following the transaction, the chief technology officer now directly owns 121,132 shares in the company, valued at $1,193,150.20. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Aura Biosciences news, insider Los Pinos Elisabet De sold 24,992 shares of the company’s stock in a transaction dated Friday, October 18th. The shares were sold at an average price of $12.04, for a total value of $300,903.68. Following the completion of the transaction, the insider now directly owns 329,847 shares of the company’s stock, valued at $3,971,357.88. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CTO Mark Plavsic sold 7,383 shares of the business’s stock in a transaction dated Wednesday, October 16th. The stock was sold at an average price of $9.85, for a total value of $72,722.55. Following the completion of the transaction, the chief technology officer now owns 121,132 shares in the company, valued at approximately $1,193,150.20. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 67,259 shares of company stock worth $780,699. 5.40% of the stock is owned by insiders.

Institutional Trading of Aura Biosciences

A number of hedge funds have recently made changes to their positions in AURA. Long Focus Capital Management LLC grew its stake in Aura Biosciences by 113.4% in the second quarter. Long Focus Capital Management LLC now owns 1,057,188 shares of the company’s stock worth $7,992,000 after purchasing an additional 561,766 shares in the last quarter. Levin Capital Strategies L.P. increased its holdings in shares of Aura Biosciences by 194.5% in the 2nd quarter. Levin Capital Strategies L.P. now owns 327,466 shares of the company’s stock valued at $2,476,000 after acquiring an additional 216,266 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of Aura Biosciences by 20.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 250,375 shares of the company’s stock valued at $1,892,000 after acquiring an additional 41,711 shares in the last quarter. Bank of New York Mellon Corp raised its position in shares of Aura Biosciences by 51.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 143,027 shares of the company’s stock valued at $1,081,000 after acquiring an additional 48,549 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in Aura Biosciences by 2.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 138,356 shares of the company’s stock worth $1,233,000 after purchasing an additional 3,612 shares during the last quarter. Institutional investors and hedge funds own 96.75% of the company’s stock.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.